Key result
Non-vitamin K oral anticoagulants were associated with a smaller decline in estimated glomerular filtration rate after percutaneous coronary intervention compared to warfarin.
Why the study?
Patients with AF on NOACs show slower renal decline than those on warfarin, and warfarin-related nephropathy has been described, but differences in renal function changes and contrast-induced nephropathy after PCI remained to be assessed.
Do non-vitamin K oral anticoagulants (NOAC) reduce the decline in renal function and occurrence of contrast-induced nephropathy compared to warfarin in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Cohort (n=420)
Yes
Do non-vitamin K oral anticoagulants (NOAC) reduce the decline in renal function and occurrence of contrast-induced nephropathy compared to warfarin in patients with atrial fibrillation undergoing percutaneous coronary intervention?
In patients with atrial fibrillation undergoing PCI, NOACs may offer a renoprotective advantage over warfarin by reducing the decline in renal function and potentially lowering the risk of contrast-induced nephropathy.
Answers are grounded in this paper and cite their sources.
NOACs were associated with less post-PCI renal decline than warfarin in AF; hypothesis-generating and should not yet change practice.
INTRODUCTION: Patients with atrial fibrillation (AF) receiving non-vitamin K oral anticoagulants (NOAC) have a slower decline in renal function than those taking warfarin. Moreover, a warfarin-related nephropathy has been described. AIM: We assessed variation of estimated glomerular filtration rate (eGFR) and occurrence of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in patients with AF taking warfarin compared with NOAC. MATERIAL AND METHODS: We retrospectively enrolled consecutive patients taking oral anticoagulation for AF undergoing PCI. The primary endpoint was variation in eGFR and serum creatinine levels within 48-72 h after PCI. The secondary endpoint was occurrence of CIN, defined as a ≥ 25% relative increase, or a ≥ 0.5 mg/dl absolute increase, in serum creatinine levels within 48-72 h. CONCLUSIONS: Patients with AF taking NOAC have a reduced decline in renal function after PCI compared with warfarin. The NOAC may be a reasonable option for patients with a high risk of developing CIN.
No takes yet. Share an insight, caveat, or question.
Montone et al. (2019) conducted a cohort in Atrial fibrillation undergoing percutaneous coronary intervention (n=420). Non-vitamin K oral anticoagulants (NOAC) vs. Warfarin was evaluated on Variation in estimated glomerular filtration rate (eGFR) within 48-72 hours after PCI (p=0.02). Non-vitamin K oral anticoagulants were associated with a smaller decline in estimated glomerular filtration rate after percutaneous coronary intervention compared to warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: